12 Affordable Biotech Stocks to Invest In Now

Page 8 of 11

4. Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Forward P/E: 12.70

Number of Hedge Fund Holders: 40

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best affordable biotech stocks to invest in now. On August 18, Morgan Stanley raised the firm’s price target on Halozyme Therapeutics, Inc. (NASDAQ:HALO) to $80 from $75, keeping an Overweight rating on the shares.

The firm told investors in a research note that the EPS 2025 guidance for Halozyme Therapeutics, Inc. (NASDAQ:HALO) has increased by 20% since January, fueled by its cost discipline and partnered products.

The analyst thus adjusted the firm’s earnings outlook to take into account the raised 2025 base and its implications for future long-term earnings guidance.

However, Goldman Sachs analyst Corinne Johnson maintained a Hold rating on Halozyme Therapeutics, Inc. (NASDAQ:HALO) on August 12, setting a price target of $56.00.

In addition to Goldman Sachs, Halozyme Therapeutics, Inc. (NASDAQ:HALO) also received a Hold from J.P. Morgan’s Jessica Fye in a report issued on August 7.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharmaceutical technology platform company that develops, manufactures, and commercializes drug-device combination products through advanced auto-injector technology.

They offer commercial or functional benefits, including increased patient comfort and adherence, and enhanced tolerability and convenience.

Page 8 of 11